Philip Ambery, Grzegorz Zajac, Joachim Almquist, Susanne Prothon, Carol Astbury, Mary N Brown, Szilard Nemes, Joselyne Nsabimana, Karl Edman, Lisa Öberg, Matti Lepistö, Goran Edenro, Inken Dillmann, Suman Mitra, Graham Belfield, Christina Keen, Tim Heise
AIMS: Corticosteroids are the treatment of choice for many inflammatory diseases but often lead to adverse effects, including hyperglycaemia. This study investigated the mechanisms driving differential effects on glucose control for AZD9567, an oral nonsteroidal selective glucocorticoid receptor modulator vs. prednisolone in 46 patients with type 2 diabetes mellitus. METHODS: In this randomized, double-blind, 2-way cross-over study (NCT04556760), participants received either AZD9567 72 mg and prednisolone 40 mg daily (cohort 1); AZD9567 40 mg and prednisolone 20 mg daily (cohort 2); or placebo and prednisolone 5 mg daily (cohort 3)...
May 1, 2024: British Journal of Clinical Pharmacology